PE20142361A1 - Peptidos terapeuticos - Google Patents

Peptidos terapeuticos

Info

Publication number
PE20142361A1
PE20142361A1 PE2014000443A PE2014000443A PE20142361A1 PE 20142361 A1 PE20142361 A1 PE 20142361A1 PE 2014000443 A PE2014000443 A PE 2014000443A PE 2014000443 A PE2014000443 A PE 2014000443A PE 20142361 A1 PE20142361 A1 PE 20142361A1
Authority
PE
Peru
Prior art keywords
antibody
inhibitor selected
peptide
therapeutic peptides
composition
Prior art date
Application number
PE2014000443A
Other languages
English (en)
Inventor
Kai W Wucherpfenning
Bettina Franz
Jr Kenneth May
Glenn Dranoff
F Stephen Hodi
Christopher Harvey
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of PE20142361A1 publication Critical patent/PE20142361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

REFERIDO A UNA COMPOSICION QUE COMPRENDE UN PEPTIDO QUE SE UNE DE MANERA INMUNOESPECIFICA A LA SECUENCIA RELACIONADA CON POLIPEPTIDO DE CMH DE CLASE I (MICA), EN LA QUE EL PEPTIDO COMPRENDE LA REGION DETERMINANTE DE COMPLEMENTARIEDAD (CDR) 3 DE LA VH DE ID DE ANTICUERPO 1, 6, 7, 8 O 9, Y LA CDR3 DE VL DE ID DE ANTICUERPO 1, 6, 7, 8 O 9, QUE CONTIENE ADEMAS UN INHIBIDOR DE HISTONA DESACETILASA (HDAC) SELECCIONADO DEL GRUPO QUE CONSISTE EN ACIDO HIDROXAMICO, VORINOSTAT, ENTRE OTROS Y UN INHIBIDOR DEL PROTEOSOMA SELECCIONADO DE BORTEZOMIB, NPI-0052, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE CANCER
PE2014000443A 2011-09-30 2012-09-28 Peptidos terapeuticos PE20142361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161541921P 2011-09-30 2011-09-30

Publications (1)

Publication Number Publication Date
PE20142361A1 true PE20142361A1 (es) 2015-01-16

Family

ID=47996757

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000443A PE20142361A1 (es) 2011-09-30 2012-09-28 Peptidos terapeuticos

Country Status (29)

Country Link
US (2) US9402905B2 (es)
EP (3) EP3210625B1 (es)
JP (2) JP2014532053A (es)
KR (2) KR102017070B1 (es)
CN (2) CN107098967A (es)
AU (1) AU2012315792B2 (es)
BR (1) BR112014007487A2 (es)
CA (1) CA2850542A1 (es)
CL (1) CL2014000786A1 (es)
CO (1) CO7020866A2 (es)
CY (1) CY1119567T1 (es)
DK (1) DK2760471T3 (es)
EA (1) EA201490644A1 (es)
ES (3) ES2619707T3 (es)
HK (2) HK1199835A1 (es)
HR (1) HRP20170494T1 (es)
HU (1) HUE034044T2 (es)
IL (1) IL231604B (es)
LT (1) LT2760471T (es)
MX (1) MX355877B (es)
NZ (2) NZ721184A (es)
PE (1) PE20142361A1 (es)
PL (1) PL2760471T3 (es)
PT (1) PT2760471T (es)
RS (1) RS55822B1 (es)
SG (1) SG11201401104WA (es)
SI (1) SI2760471T1 (es)
TN (1) TN2014000134A1 (es)
WO (1) WO2013049517A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665090A1 (en) * 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
ES2619707T3 (es) 2011-09-30 2017-06-26 Dana-Farber Cancer Institute, Inc. Péptidos terapéuticos
EP2812027A1 (en) * 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
MX2015011075A (es) * 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
CA2906356A1 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
US9803017B2 (en) 2013-07-05 2017-10-31 University Of Washington Through Its Center For Commercialization Soluble MIC neutralizing monoclonal antibody for treating cancer
WO2015085210A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2939006A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US20170198054A1 (en) * 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
EA201891287A1 (ru) 2015-12-04 2018-11-30 Дана-Фарбер Кэнсер Инститьют, Инк. Вакцинация с использованием альфа 3-домена mica/b для лечения рака
US10448746B2 (en) * 2016-03-15 2019-10-22 Nadia Galloway Bed sheet with an integrated body positioner
CA3016765A1 (en) * 2016-03-15 2017-09-21 Innate Pharma Anti-mica antibodies
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
AU2017344411A1 (en) 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
CN110267678A (zh) * 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
CN110494450A (zh) 2017-03-31 2019-11-22 百时美施贵宝公司 ***的方法
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
RU2020128010A (ru) * 2018-01-25 2022-02-25 Каллинен Майка Корп. Антитела к mica/b и способы применения
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
WO2020035345A1 (en) * 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CN113637077B (zh) * 2021-10-14 2021-12-24 尚健单抗（北京）生物技术有限公司 一种抗mica的抗体及其应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
GB8709290D0 (en) 1987-04-16 1987-05-20 Secretary Trade Ind Brit Precision motion slideways
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP0937258A2 (en) 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
MXPA02007733A (es) 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
WO2002068615A2 (en) 2001-02-28 2002-09-06 Fred Hutchinson Cancer Research Center, Inc. Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
US6566208B2 (en) 2001-07-25 2003-05-20 Chartered Semiconductor Manufacturing Ltd. Method to form elevated source/drain using poly spacer
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
RU2004133894A (ru) 2002-04-22 2005-04-20 Юниверсити Оф Флорида (Us) Функционализированные наночастицы и способы их применения
CA2483343A1 (en) * 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7628986B2 (en) 2003-06-27 2009-12-08 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP2154157A3 (en) 2004-01-12 2010-04-28 Applied Molecular Evolution Inc. FC region variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005097160A2 (en) * 2004-04-05 2005-10-20 The Regents Of The University Of California Modulation of nkg2d
CA2779559A1 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution Inc. Variant fc regions
MX2007004247A (es) * 2004-10-19 2007-06-12 Amgen Inc Agentes de aglutinacion especifica a angiopoyetina-2.
BRPI0516962A (pt) 2004-10-25 2008-09-30 Univ Northwestern anticorpo isolado, ou fragmento do mesmo, composição farmacêutica, métodos para prevenir a ligação de ligantes difundìveis derivados de abeta a um neurÈnio, para inibir a constituição de ligantes difundìveis, para bloquear a fosforilação de proteìna, para tratar profilaticamente ou terapeuticamente uma doença, para identificar um agente terapêutico, para detectar ligantes difundìveis, e para diagnosticar uma doença, e, kit para detectar ligantes difundìveis
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
RU2394839C2 (ru) * 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
EP1928872B1 (en) * 2005-09-21 2012-03-14 4Sc Ag Novel sulphonylpyrroles as inhibitors of hdac
US8248965B2 (en) 2005-11-03 2012-08-21 Motorola Solutions, Inc. Method and apparatus regarding use of a service convergence fabric
JP2009514528A (ja) 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
NZ569787A (en) * 2005-12-15 2011-07-29 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
DE102006009847A1 (de) 2006-03-01 2007-09-06 Sweredjuk, Robert, Dr. Verfahren von Absorbieren von Schadstoffen und Gerüchen
BRPI0715396B8 (pt) 2006-08-07 2021-05-25 Harvard College método de produção de uma composição para vacina
US20110060120A1 (en) 2006-09-08 2011-03-10 Obeid Michel Sarkis Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
EP2083852B1 (en) * 2006-10-04 2014-12-10 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP1944611A1 (en) * 2007-01-11 2008-07-16 Université de la Méditerranée Biomarker for the medicine and the biology of the reproduction
US7959916B2 (en) 2007-04-23 2011-06-14 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by ERp5
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8685393B2 (en) * 2008-03-24 2014-04-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of systemic anthrax infection
US8182809B1 (en) 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8207497B2 (en) 2009-05-08 2012-06-26 Ionsense, Inc. Sampling of confined spaces
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101688522B1 (ko) 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
ES2547142T5 (es) * 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
CN102911270A (zh) * 2011-08-05 2013-02-06 浙江大学 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
ES2619707T3 (es) 2011-09-30 2017-06-26 Dana-Farber Cancer Institute, Inc. Péptidos terapéuticos
EP2812027A1 (en) * 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
MX2015011075A (es) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
JP6002833B2 (ja) 2013-03-28 2016-10-05 本田技研工業株式会社 報知システム、電子装置、報知方法、およびプログラム
US9572898B2 (en) 2013-09-09 2017-02-21 Seton Hall University Functionalized fluorine containing phthalocyanine molecules
WO2015085210A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2939006A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US20170198054A1 (en) 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies

Also Published As

Publication number Publication date
HK1243427A1 (zh) 2018-07-13
MX2014003601A (es) 2014-05-28
EP3628329A1 (en) 2020-04-01
ES2757473T3 (es) 2020-04-29
CY1119567T1 (el) 2018-03-07
PL2760471T3 (pl) 2017-07-31
SG11201401104WA (en) 2014-09-26
ES2619707T3 (es) 2017-06-26
JP2014532053A (ja) 2014-12-04
WO2013049517A3 (en) 2014-05-08
EP2760471A2 (en) 2014-08-06
KR20190112756A (ko) 2019-10-07
US10793633B2 (en) 2020-10-06
US9402905B2 (en) 2016-08-02
DK2760471T3 (en) 2017-05-08
LT2760471T (lt) 2017-04-25
US20170008962A1 (en) 2017-01-12
SI2760471T1 (sl) 2017-04-26
EP3210625B1 (en) 2019-08-28
EP2760471B1 (en) 2017-02-01
NZ721184A (en) 2018-08-31
KR102017070B1 (ko) 2019-09-02
US20140004112A1 (en) 2014-01-02
NZ623086A (en) 2016-08-26
CL2014000786A1 (es) 2014-11-14
EP2760471B9 (en) 2017-07-19
RS55822B1 (sr) 2017-08-31
EA201490644A1 (ru) 2014-09-30
AU2012315792B2 (en) 2017-09-07
CN103958543B (zh) 2016-12-14
TN2014000134A1 (en) 2015-07-01
HK1199835A1 (en) 2015-07-24
JP2018048139A (ja) 2018-03-29
BR112014007487A2 (pt) 2017-04-04
CO7020866A2 (es) 2014-08-11
AU2012315792A1 (en) 2014-04-17
HRP20170494T1 (hr) 2017-06-02
IL231604B (en) 2018-08-30
KR20140076600A (ko) 2014-06-20
KR102225422B1 (ko) 2021-03-08
HUE034044T2 (en) 2018-01-29
EP2760471A4 (en) 2015-06-03
EP3210625A2 (en) 2017-08-30
EP3628329B1 (en) 2022-08-10
IL231604A0 (en) 2014-05-28
CN107098967A (zh) 2017-08-29
ES2925654T3 (es) 2022-10-19
WO2013049517A2 (en) 2013-04-04
PT2760471T (pt) 2017-03-22
EP3210625A3 (en) 2017-10-25
MX355877B (es) 2018-05-03
CN103958543A (zh) 2014-07-30
CA2850542A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
PE20142361A1 (es) Peptidos terapeuticos
JP2016516059A5 (es)
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
PE20141454A1 (es) Inmunotoxina recombinante dirigida a la mesotelina
PE20131209A1 (es) Anticuerpos anti-fap
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
BR112019002848A2 (pt) anticorpo anti-lag-3
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
RU2019118359A (ru) Антитело к cd73 человека
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
JP2014532053A5 (es)
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20140247A1 (es) Anticuerpos anti-cd38
UA117294C2 (uk) Імунокон'югат
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201691251A1 (ru) Цитотоксические пептиды и их конъюгаты
BR112015022978A2 (pt) agente de ligação biespecífico, seu método de produção composição farmacêutica, proteína de fusão, uso, sequência de ácido nucleico, vetor, célula hospedeira, método de matar células tumorais e de inibir o crescimento tumoral
PE20131334A1 (es) Anticuerpo igg1 humanizado
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
RU2014133410A (ru) Антитело к blys
EA201370076A1 (ru) Иммуноглобулины-переносчики и их применение
PE20141017A1 (es) Anticuerpos del cea

Legal Events

Date Code Title Description
FC Refusal